Sánchez Torres G, Gallo Santa E, Cruz Robles J L
Arch Inst Cardiol Mex. 1978 Nov-Dec;48(6):1142-60.
The antihypertensive effect of the following therapeutic regimens: diuretic alone (DA), diuretic plus sympathetic inhibitor (DSI), diuretic plus betablocker (DB) and diuretic plus, betablocker plus vasodilator (DBV) was studied for 34.1 +/- 5.4 months in 28 patients with resistant essential hypertension (REH). Depending of treatment tolerability and the optimal antihypertensive action of drugs 21, 24, 26 and 10 cases were treated continuously or alternately with DA (9.9), DSI (15.0), DB (4.8), and DBV (14.6), respectively (in paragraph average duration of treatment in months). On admission the 89.3% and 42.8% of population had electrocardiographic signs of left ventricular hypertrophy or past-history of cardio-vascular complications, respectively. Arithmethic average and standard deviation of individual changes of systolic and diastolic blood pressure obtained during DA, DSI, DB and DBV treatment were -32.4 +/- 31.8, -19.3 +/- 27.2, -18.9 +/- 15.9 and -18.2 +/- 21.3 for systolic and -35.8 +/- 20.2, -12.3 +/- 17.2, -15.1 +/- 16.9 and -15 +/- 13.1 (mm. de Hg.) for diastolic blood pressure respectively. Average blood pressure before treatment was 222.4 +/- 30.3/128.0 +/- 20.8 (mm of Hg) and under the most effective treatment was 175.5 +/- 21.8/106.5 +/- 12.1 with a p less than or equal to 0.001 for either sistolic and diastolic pressure. There were not significant regressive electrocardiographic changes during the therapeutic period, neither significant changes in urea and creatinine blood values. 46.4% and 25% of cases exhibited collateral drug symptoms and cardio-vascular no fatal complications, respectively. Three of the last group patients died outside of the Hospital (2 sudden deaths and 1 renal insufficiency death). RH still constitutes a challenge to medical therapy. Nevertheless individualized therapy may modify the natural history of this hypertensive variety.
对28例顽固性原发性高血压(REH)患者进行了34.1±5.4个月的研究,观察了以下治疗方案的降压效果:单用利尿剂(DA)、利尿剂加交感神经抑制剂(DSI)、利尿剂加β受体阻滞剂(DB)以及利尿剂加β受体阻滞剂加血管扩张剂(DBV)。根据治疗耐受性和药物的最佳降压作用,分别有21例、24例、26例和10例患者持续或交替接受DA(9.9个月)、DSI(15.0个月)、DB(4.8个月)和DBV(14.6个月)治疗(括号内为平均治疗持续时间,单位为月)。入院时,分别有89.3%和42.8%的患者有左心室肥厚的心电图表现或有心血管并发症病史。在DA、DSI、DB和DBV治疗期间,收缩压和舒张压个体变化的算术平均值及标准差分别为:收缩压-32.4±31.8、-19.3±27.2、-18.9±15.9和-18.2±21.3,舒张压-35.8±20.